 Patients who have had anticancer therapy chemotherapy, radiotherapy, vaccines and hormone therapy with the exception of GnRH agonists within the last 4 weeks 6 weeks for nitrosoureas or mitomycin C or UCN-01; or those who have not recovered from adverse events reduce to grade 2 or less due to agents administered more than 4 weeks earlier. Patients must be greater than or equal to 2 weeks since any investigational agent administered as part of a Phase 0 study. 